Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 3/20 | 0.58 |
| ▸ | KDR | P35968 | 15/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.56 |
| ▸ | KIT | P10721 | 3/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.56 |
| ▸ | MET | P08581 | 6/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.53 |
| ▸ | AURKA | O14965 | 4/20 | 0.53 |
| ▸ | TEK | Q02763 | 4/20 | 0.53 |
| ▸ | FLT1 | P17948 | 4/20 | 0.51 |
| ▸ | RET | P07949 | 3/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | FLT4 | P35916 | 2/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | STK10 | O94804 | 1/20 | 0.51 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12412019 | 0.95 | AXL (0.57) | AXLKDRPDGFRAKITFGFR2 | |
| SCHEMBL1895346 | 0.94 | AXL (0.58) | AXLKDRPDGFRAKITFGFR2 | |
| SCHEMBL1250601 | 0.93 | KDR (0.64) | AXLKDRPDGFRAKITFGFR2 | |
| SCHEMBL13613025 | 0.91 | KDR (0.59) | AXLKDRPDGFRAKITFGFR2 | |
| SCHEMBL1893087 | 0.89 | KDR (0.71) | AXLKDRPDGFRAKITFGFR2 | |
| SCHEMBL1896539 | 0.88 | AXL (0.69) | AXLKDRPDGFRAKITMET | |
| SCHEMBL3503393 | 0.88 | AXL (0.63) | AXLKDRPDGFRAKITFGFR2 | |
| SCHEMBL1892458 | 0.88 | KDR (0.62) | AXLKDRPDGFRAKITFGFR2 | |
| SCHEMBL1890151 | 0.87 | AXL (0.72) | AXLKDRPDGFRAKITFGFR2 | |
| SCHEMBL1895078 | 0.87 | AXL (0.63) | AXLKDRPDGFRAKITFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | FUNAHASHI YASUHIRO | 2011-05-19 | — | — | US | disclosed |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7612092-B2 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | GNG2, GCG, FRG1 | AXL 3210/4885KDR 2687/4885PDGFRA 3131/4885 |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | GNG2, GCG, FRG1 | AXL 3184/4885KDR 2782/4885PDGFRA 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.